What is glofitamab?
Glofitamab-gxbm is an immunotherapy treatment that may be used to treat adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified or large B-cell lymphoma arising from follicular lymphoma, after at least 2 lines of systemic therapy. Glofitamab-gxbm is approved under the name Columvi.
Large B-cell lymphoma is an aggressive type of non-Hodgkin’s lymphoma (NHL) resulting from the malignant proliferation of B cells during their various stages of development. LBCL is one of the most prevalent types of blood cancer among adults.
Glofitamab-gxbm represents a much needed further treatment option for B-cell lymphoma patients and its approval was based on impressive results including a 56% overall response rate and a complete response rate of 43%. 68.5% of patients experienced a long-lasting response of 9 months or longer (median duration of response, 18.4 months).
Columvi belongs to a new class of medicines known as CD20×CD3 T-cell engaging bispecific monoclonal antibodies. It was granted accelerated approval by the FDA on June 15, 2023.
References
- Shirley M. (2023). Glofitamab: First Approval. Drugs, 1–7. Advance online publication. https://doi.org/10.1007/s40265-023-01894-5
- Max S. Topp, Monica Tani, Michael Dickinson, Nilanjan Ghosh, Armando Santoro, Antonio Pinto, Francesc Bosch, Christopher P. Fox, Armando López-Guillermo, Claudia Carlucci, Chun Wu, Kathryn Humphrey, Pauline Baumlin, Martin Barrett, Naseer Qayum, Franck Morschhauser; Glofitamab Plus R-CHOP Induces High Response Rates and a Favorable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Phase Ib Study. Blood 2022; 140 (Supplement 1): 1775–1777. doi: https://doi.org/10.1182/blood-2022-157732
- Wang, C., Liu, Y. Glofitamab therapy for diffuse large B cell lymphoma: latest updates from the 2022 ASH Annual Meeting. J Hematol Oncol 16, 20 (2023). https://doi.org/10.1186/s13045-023-01420-w
- Dickinson, M. J., Carlo-Stella, C., Morschhauser, F., Bachy, E., Corradini, P., Iacoboni, G., Khan, C., Wróbel, T., Offner, F., Trněný, M., Wu, S. J., Cartron, G., Hertzberg, M., Sureda, A., Perez-Callejo, D., Lundberg, L., Relf, J., Dixon, M., Clark, E., Humphrey, K., … Hutchings, M. (2022). Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. The New England journal of medicine, 387(24), 2220–2231. https://doi.org/10.1056/NEJMoa2206913
Read next
What are Monoclonal Antibodies and how do they work?
Monoclonal antibodies (mAbs) are man-made proteins that mimic the natural antibodies produced by our immune systems. Monoclonal antibodies can be formulated into medicines to treat various types of illnesses, such as cancer, rheumatoid arthritis or psoriasis.
Continue reading
What is the cost of Kymriah?
Kymriah (tisagenlecleucel) is an expensive CAR-T cell cancer therapy costs over $633,000 for one treatment, but most people do not pay this amount. In addition, the Centers for Medicare & Medicaid Services (CMS) states that CAR-T cell therapy would be covered for eligible people with Medicare.
Continue reading
What is the cost of Yescarta?
The cost of Yescarta is about $424,000 per treatment regimen, but most people do not pay this amount. Your insurance or the manufacturer may cover many of the costs for this treatment. Each dose of Yescarta is a customized treatment created using a patient’s own immune system to help fight lymphoma (a type of blood cancer).
Continue readingSee also:
Related medical questions
- Is Adcetris a chemotherapy drug?
- What is the success rate of Epkinly?
- What is the survival rate of Kymriah?
- What is the success rate of Breyanzi?
- How is Kymriah administered?
- How is Yescarta administered?
- What type of drug is Yescarta (axicabtagene ciloleucel)?
Drug information
Related support groups
- Columvi (2 questions, 3 members)
- Glofitamab (1 questions, 3 members)
- B Cell Lymphoma (10 questions, 3 members)